Disappointing results for liraglutide in type 1 diabetes
25 August 2015 | By Victoria White
Novo Nordisk has announced headline results from the final Phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes...
List view / Grid view
News
Data findings highlight common misconceptions about concussion
24 August 2015 | By Victoria White
New data from Abbott's Concussion IQ Survey reveals that many adults lack basic understanding about concussion signs, symptoms, risk and treatment...
Phase III study data for Fycompa in PGTC seizures published
24 August 2015 | By Victoria White
Phase III study results for Eisai’s Fycompa® (perampanel) in primary generalised tonic-clonic (PGTC) seizures have been published for the first time...
Real world ETNA registries of new once-daily edoxaban start in Europe
24 August 2015 | By Victoria White
ETNA registries have commenced in Europe to collect a robust set of information on how once-daily edoxaban is being used in real world settings...
Bavituximab and durvalumab combo to be evaluated in solid tumours
24 August 2015 | By Victoria White
AstraZeneca and Peregrine Pharmaceuticals are to evaluate the safety and efficacy of Peregrine’s bavituximab in combination with AstraZeneca’s durvalumab...
Positive topline results from two Phase 3 studies of Trumenba
21 August 2015 | By Victoria White
Pfizer has announced positive topline results of two Phase 3 studies of Trumenba (Meningococcal Group B Vaccine). Both studies met all primary endpoints...
Novartis pays $1 billion to bolster its pipeline with ofatumumab
21 August 2015 | By Victoria White
Novartis is to acquire all remaining rights to GSK's ofatumumab to develop treatments for MS and other autoimmune indications...
Janssen submits Extension MAA for paliperidone palmitate once-every-three-months formulation
21 August 2015 | By Victoria White
Janssen has submitted an Extension MAA to the EMA for paliperidone palmitate once-every-three-months formulation for the treatment of schizophrenia...
EMA validates R/F/TAF MAA for the treatment of HIV-1
21 August 2015 | By Victoria White
An MAA for an investigational regimen that combines emtricitabine, tenofovir alafenamide and rilpivirine (R/F/TAF) has been fully validated by the EMA...
Coulter Partners appoints PR and Marketing Manager
21 August 2015 | By Coulter Partners
Global Life Sciences search specialist, Coulter Partners is pleased to announce the appointment of Alison James as PR and Marketing Manager...
Dolomite Flow Chemistry Systems launched at 250th ACS Exposition
21 August 2015 | By Dolomite
Dolomite, a world leader in microfluidics innovation, has launched new flexible, cost-effective Flow Chemistry Systems at the 250th American Chemical Society Meeting and Exposition in August 2015...
EMA validates MAA for Pfizer’s Ibrance
21 August 2015 | By Victoria White
The EMA has validated for review a MAA for Ibrance in combination with endocrine therapy for the treatment of HR+/HER2- metastatic breast cancer...
EMA accepts MAA for multiple myeloma drug ixazomib
21 August 2015 | By Victoria White
Takeda has announced that the EMA has accepted is Marketing Authorisation Application for ixazomib for the treatment of patients with multiple myeloma...
EC approves Odomzo for basal cell carcinoma
20 August 2015 | By Victoria White
The EC has approved Novartis’ Odomzo (sonidegib) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma...
Multiple myeloma treatment market value to approach $9 billion by 2021
20 August 2015 | By Victoria White
The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, says GBI Research...
